Company Overview

Xenitra Limited (XEN) is an ASX- listed company specialises in fast-moving consumer goods (FMCG), nutraceuticals, over-the-counter (OTC) medicine and personal care products that are sold through a channel optimised sales ecosystem including blockchain tokenised distribution channels spanning Business-to-Business (B2B) trading, retail distribution and all major ecommerce platforms in China. Xenitra is an established brand acceleration partner for western brands entering the Asian markets. Through XEN proprietary platform, the Company have a proven track record of delivering exceptional market integration, providing marketing insights and delivering sales velocity.

Xenitra has established itself as a proven brand acceleration platform, connecting Western consumer brands with high-growth Asian markets, particularly China. Through its proprietary sales ecosystem spanning B2B trading, ecommerce platforms, and retail distribution, the Company has delivered more than $70 million in sales since 2024, demonstrating both execution capability and strong market demand.

Following a period of restructuring and strategic refocus, Xenitra is now entering its next phase of growth, underpinned by two high-margin business verticals that we believe will materially enhance both revenue growth and profitability.

The Offer

Xenitra is undertaking a capital raise of up to $1.50 million at an issue price of $0.003 per share (“Offer Price”). The offer includes one free attaching option for every two shares subscribed (1:2), with each option exercisable at $0.004 on or before 2 April 2028. The options are intended to be listed, subject to shareholder approval.

The Offer Price represents a 25% discount to the company’s last trading price of .04C.

For professional and s708 investors only

Investment Highlights

• Proven revenue base and operating platform
• Established B2B + ecommerce infrastructure across China
• High-margin OTC Medicines – “Next Daigou - Opportunity”.  Scalable across:
  • Ecommerce
  • Hospital supply chains
  • Cross-border logistics
• A first-mover RWA tokenisation platform with real revenue backing

Use of Funds

Funds raised will be deployed to:

• Accelerate OTC medicines expansion
• Scale the OPAL RWA token ecosystem across new brands
• Support working capital and infrastructure required for growth

The Opportunity

We believe Xenitra is uniquely positioned at the intersection of:

• China consumer demand
• Cross-border ecommerce
• High-margin healthcare distribution
• Tokenised commerce innovation

This creates a rare opportunity to invest in a company with:

• Existing scale and revenues
• Multiple near-term growth catalysts
• A clear pathway to margin expansion and market re-rating